699 results match your criteria: "Cutaneous CD30+ Ki-1 Anaplastic Large-Cell Lymphoma"
Primary Cutaneous Anaplastic Large Cell Lymphoma With Rare Extracutaneous Disseminated Disease: A Case Report.
Am J Dermatopathol
December 2024
Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA; and.
Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a CD30+ lymphoproliferative disorder with generally favorable outcomes and infrequent extracutaneous spread, usually limited to local lymph nodes. However, there may be extensive histologic overlap with more aggressive CD30+ lymphomas, such as large cell transformation of mycosis fungoides or secondary skin involvement by anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma. Definitive diagnosis relies on clinicopathologic correlation.
View Article and Find Full Text PDFRapidly enlarging primary cutaneous anaplastic large T-cell lymphoma of the eyelid: A case report.
J Pak Med Assoc
November 2024
Final Year MBBS Student, Jinnah Postgraduate Medical Center, Karachi, Pakistan.
Non-Hodgkin CD30+ T-cell lymphoproliferative disease encompasses three subgroups, one of which is primary cutaneous anaplastic large T-cell lymphoma (PC-ALCL). It is distinguished by the presence of giant anaplastic cells with pleomorphism and widespread CD30 positivity. The case of a 58-year-old female is presented who reported to the Eye Department of Jinnah Post-Graduate Medical Centre (JPMC) on 18th January, 2023 with a three-month history of rapidly enlarging, non-tender, ulcerated lesion on the lower eyelid of the right eye.
View Article and Find Full Text PDFAnaplastic Large B-Cell Lymphoma: Cutaneous Presentations.
Cureus
October 2024
Department of Dermatology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Article Synopsis
- Anaplastic large cell lymphoma (ALCL) is a rare T-cell lymphoma marked by the presence of CD30 and can often be mistaken for other conditions due to its vague symptoms.
- A 10-year-old girl initially treated for a bacterial infection was later diagnosed with ALK-negative ALCL after a biopsy revealed the disease, with additional imaging showing lung involvement and a Murphy stage II classification.
- The case highlights the necessity of early biopsy and molecular testing when initial treatments don't work, emphasizing that prompt diagnosis and thorough examinations can significantly enhance treatment success and patient prognosis.
[Cutaneous T-cell lymphomas].
Bull Cancer
November 2024
Service de dermatologie et oncologie cutanée, centre hospitalier Estaing, CHU de Clermont-Ferrand, université Clermont-Auvergne, place Lucie-Aubrac, 63000 Clermont-Ferrand, France. Electronic address:
Article Synopsis
- Primitive cutaneous T-cell lymphomas are skin-specific lymphomas, distinct from systemic lymphomas affecting the skin.
- The most common types include mycosis fungoides, CD30+ lymphoproliferations, and erythrodermic T-cell lymphomas, with several rarer forms also identified.
- Diagnosis relies on clinical skin exams and biopsies, enhanced by molecular genetics, while treatments are categorized into five main types, including skin therapies and immunotherapies.
Diagnostic and management challenges in primary cutaneous anaplastic large cell lymphoma with necrosis, inflammation, and surgical intervention: A case report.
World J Clin Cases
November 2024
Department of Plastic Reconstructive Surgery, Chosun University College of Medicine, Gwangju 61453, South Korea.
Background: Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) poses significant diagnostic difficulties due to its similarity in the appearance of skin lesions with chronic inflammatory disorders and other dermatological conditions. This study aims to investigate these challenges by conducting a comprehensive analysis of a case presenting with PC-ALCL, emphasizing the necessity of accurate differentiation for appropriate management.
Case Summary: An 89-year-old female patient with diabetes and hypertension presented with arm and abdominal ulcerated mass lesions.
Lymphomatoid Papulosis With DUSP22 Rearrangement in a Patient With a Historical Diagnosis of Primary Cutaneous Anaplastic Large Cell Lymphoma.
Cureus
August 2024
Department of Pathology - Hematopathology and Dermatopathology, Creighton University School of Medicine, Omaha, USA.
Article Synopsis
- Lymphomatoid papulosis (LyP) with rearrangement is a rare subtype characterized by two types of T-cells: small- to medium-sized weakly CD30+ cells and medium- to large-sized strongly CD30+ cells.
- This subtype has a generally milder clinical course than primary cutaneous anaplastic large cell lymphoma (pcALCL) and often regresses without treatment.
- A notable case involved an 81-year-old woman who was diagnosed with LyP with rearrangement, having had a previous diagnosis of pcALCL 20 years earlier.
Systemic ALK-negative anaplastic large cell lymphoma with NPM1::TYK2 rearrangement.
J Hematop
December 2024
Department of Pathology, University of Colorado Hospital, University of Colorado School of Medicine, 12605 East 16 Avenue, Aurora, CO, 80045, USA.
Article Synopsis
- Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma, primarily characterized by ALK gene rearrangements, though about 20-50% are ALK negative (ALK- ALCL) and display different genetic changes.
- A unique case of systemic ALK- ALCL involved a genetic fusion (NPM1::TYK2) that complicated diagnosis until next-generation sequencing (NGS) was applied.
- The NGS results revealed clonal rearrangement and a previously unreported NPM1::TYK2 fusion in systemic ALK- ALCL, highlighting its significance and rarity in comparison to other lymphoid conditions.
Cutaneous Lymphoma in a Tertiary Skin Hospital and Referral Centre in Nepal.
J Nepal Health Res Counc
June 2024
DI Skin Hospital and Referral Centre Private Ltd, Bansbari, Budanilkantha, Kathmandu, Nepal.
Article Synopsis
- Primary cutaneous lymphomas are rare skin cancers that do not have lymphomas outside the skin when they are diagnosed, and there is currently no data on this condition in Nepal.
- This study looked at 15 cases of cutaneous lymphomas diagnosed at a hospital in Kathmandu, with patients having a median age of 45 years and more males than females.
- The findings showed that 87% of the lymphomas were T-cell types, with mycosis fungoides being the most common subtype, while only 13% were B-cell lymphomas.
DUSP22-rearranged primary cutaneous CD30-positive T-cell lymphoproliferative disorders and adult T-cell leukemia/lymphoma frequently share the LEF1+/TIA1- immunophenotype.
Hum Pathol
August 2024
Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan; Department of Pathology, Taipei Medical University Hospital, Taipei, 110, Taiwan; Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan. Electronic address:
Article Synopsis
- DUSP22 rearrangements are genetic changes found in certain types of lymphomas, particularly in systemic and primary cutaneous anaplastic large cell lymphoma, as well as lymphomatoid papulosis, with previous studies mainly highlighting S-ALCL.
- This study examined LEF1/TIA1 expression and MSC mutations in 23 cases of C-ALCL and LyP, finding DUSP22 rearrangements in eight cases and LEF1 expression present in 63% of those cases, while TIA1 was negative across the board.
- The research indicated that the rate of LEF1 expression in DUSP22-rearranged C-ALCL/LyP is lower than that in S-ALCL
[Clinicopathological features of primary mucosal CD30-positive T-cell lymphoproliferative disorders].
Zhonghua Bing Li Xue Za Zhi
July 2024
Department of Pathology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100050, China.
Article Synopsis
- The study focused on the clinicopathological features and differential diagnosis of primary mucosal CD30-positive T-cell lymphoproliferative disorders (pmCD30TLPD) by reviewing cases diagnosed between 2013 and 2023.
- Eight cases were analyzed, revealing that most patients were middle-aged, with lesions primarily in the oral and anal mucosa, showing various morphological characteristics and immunophenotypes.
- Despite the potential for misdiagnosis with other lymphoproliferative disorders, most patients had favorable outcomes, with only one succumbing to complications, emphasizing the importance of careful diagnosis and monitoring.
Intraoral CD30+ T-Cell Lymphoproliferative Disorder with Lymphomatoid Papulosis Type C Features Mimics Lymphoma Histopathologically and Immunohistochemically.
Head Neck Pathol
June 2024
Oral Pathology, Department of Stomatology, Public Oral Health, and Forensic Dentistry, Ribeirão Preto Dental School, University of São Paulo (FORP/USP), Ribeirão Preto, SP, 14040-904, Brazil.
Article Synopsis
- * Histopathology revealed atypical lymphoid cells showing specific markers, raising concerns for anaplastic large cell lymphoma (ALCL), though the ulcer healed completely within three weeks.
- * The authors conclude that this case represents a rare type of intraoral CD30+ T-cell LPD, which they believe corresponds to cutaneous LyP type C, highlighting its diagnostic challenges.
Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
J Dermatol
August 2024
Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Article Synopsis
- - Brentuximab vedotin (BV) is an effective treatment for refractory CD30+ mycosis fungoides and primary cutaneous anaplastic large-cell lymphoma, showing promising results in a study with Japanese patients.
- - The study involved two groups: one with CD30+ mycosis fungoides and pcALCL, and another with different CD30+ lymphoproliferative disorders, with treatment cycles continuing based on patient response.
- - The primary endpoint demonstrated a high objective response rate (69.2% for cohort 1 and 62.5% for cohort 2), with manageable side effects such as peripheral neuropathy and fever in some patients.
Primary cutaneous, epidermotropic mycosis fungoides-like presentation: critical appraisal and description of two novel cases, broadening the spectrum of ALK+ T-cell lymphoma.
Virchows Arch
September 2024
Division of Hematology, ASST ValleOlona Ospedale di Busto Arsizio, Busto Arsizio, Italy.
Article Synopsis
- This text discusses two patients diagnosed with epidermotropic T-cell lymphoma that exhibited characteristics similar to mycosis fungoides (MF) and expressed ALK, prompting an analysis of ALK+ primary cutaneous T-cell lymphomas (pcTCL).
- It highlights the unique histological features of these MF-like cases, which include specific cell types and expressions of certain markers, and emphasizes the need for careful investigation for ALK expression.
- The text also addresses the rarity of bona fide ALK+ pcTCL, the challenges in diagnosis due to potential misinterpretation, and the lack of conclusive data on treatment strategies, suggesting that MF-like management may be used while considering targeted therapies in advanced cases.
Brentuximab-induced pneumonitis and organizing pneumonia: a case report with literiture review.
Ann Med Surg (Lond)
May 2024
Mayo Clinic Hospital, Scottsdale, AZ.
Article Synopsis
- Brentuximab vedotin (BV) is an anti-cancer drug approved for treating various lymphomas, known for being generally well-tolerated, but can cause rare side effects like lung toxicity.
- A case study of a woman in her forties with cutaneous T-cell lymphoma revealed that she developed serious respiratory issues due to BV, confirmed to be BV-induced pneumonitis after ruling out other causes through tests.
- Prompt recognition and treatment by discontinuing BV and using steroids led to a significant recovery, highlighting the need for doctors to be vigilant about this potential side effect in cancer patients.
Primary cutaneous anaplastic large-cell lymphoma resembling infratemporal space infection: a case report.
BMC Oral Health
April 2024
Department of Oral and Maxillofacial Reconstruction, the Affiliated Hospital of Qingdao University, Qingdao, 266555, China.
Article Synopsis
- Primary cutaneous anaplastic large-cell lymphoma (PC-ALCL) is a rare type of T-cell lymphoma, and a case involving the temporal region is particularly uncommon.
- A 78-year-old woman presented with facial swelling and pain, initially suspected to be an infection, but her biopsy revealed PC-ALCL instead of infection-related pus.
- The case highlights the importance of conducting thorough biopsies and using immunohistochemistry for accurate diagnosis of PC-ALCL to avoid misdiagnosis.
Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma.
Mol Clin Oncol
May 2024
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Article Synopsis
- About 26% of adults with ALK-positive pcALCL developed systemic involvement, while a significant number of pediatric cases (36%) showed both systemic and cutaneous disease.
- The study suggests that ALK expression alone does not effectively differentiate between pcALCL and sALCL, indicating that localized treatment and careful monitoring may be sufficient for ALK-positive pcALCL cases.
Risk of systemic lymphoma in patients with cutaneous CD30+ lymphoproliferative disorders: A single center retrospective cohort analysis.
J Am Acad Dermatol
July 2024
Department of Dermatology, University of Washington, Seattle, Washington.
Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Virchows Arch
March 2024
Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Article Synopsis
- Brentuximab vedotin (BV) is an antibody drug used to treat anaplastic large cell lymphoma (ALCL) and classic Hodgkin lymphoma (CHL), as well as other CD30-positive lymphomas.
- A study analyzed 12 CHL and 9 ALCL patients after BV therapy, finding that 44% of ALCL patients experienced a loss or decrease of CD30 expression, while all CHL patients maintained consistent CD30 levels.
- Patients with decreased CD30 expression received higher cumulative doses of BV and had lower initial CD30 expression; however, this decrease was not linked to specific subtypes of ALCL.
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin.
J Clin Med
January 2024
Department of Dermatology, Medical University of Lodz, 90-647 Lodz, Poland.
One of the most common subgroups of cutaneous T-cell lymphomas is that of primary cutaneous CD30-positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as well as some borderline cases. Recently, significant progress has been made in understanding the genetics and treatment of these disorders.
View Article and Find Full Text PDFA Rare and Isolated Presentation of Primary Cutaneous Anaplastic Large Cell Lymphoma on the Breast.
Cureus
November 2023
Dermatology, Sheikh Khalifa Medical City, Abu Dhabi, ARE.
Article Synopsis
- Primary cutaneous anaplastic large-cell lymphoma (PC-ALCL) is a type of non-Hodgkin lymphoma that mainly affects the skin and makes up about 25% of cutaneous T-cell lymphomas.
- It usually appears as reddish-brown nodules on the skin, sometimes developing into ulcers, and while some cases may regress, complete resolution is rare.
- The text also describes a unique case of a 26-year-old woman with PC-ALCL who had no history of breast implants, highlighting the differences between ALK-positive and ALK-negative subtypes, particularly in breast presentations.
Pediatric primary cutaneous anaplastic large-cell lymphoma with associated hypovitaminosis D.
Arch Dermatol Res
December 2023
Dermatology, University of Central Florida College of Medicine, Orlando, FL, USA.
Article Synopsis
- - CD30+ lymphoproliferative diseases (LPDs) are rare, particularly in children, and distinguishing between lymphomatoid papulosis and cutaneous anaplastic large-cell lymphoma (ALCL) is vital due to differing treatment needs.
- - This text presents a unique case of primary cutaneous ALCL in a Hispanic child with low vitamin D levels, emphasizing the importance of vitamin D testing in patients with cutaneous lymphoma.
- - A holistic treatment approach for pediatric PC-ALCL is suggested, involving minimally invasive methods such as shave removal and topical steroids, along with addressing potential comorbidities like hypovitaminosis D.
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.
Blood Res
December 2023
Department of Hematology and Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Korea.
Article Synopsis
- Brentuximab vedotin (BV) is an antibody-drug conjugate approved in Korea for treating relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, but there's limited real-world data on its effectiveness.
- In a study involving 85 patients, BV showed high efficacy rates with an objective response rate (ORR) of 85.4% for HL, 88% for ALCL, and 92% for mycosis fungoides (MF), with median progression-free survival times of approximately 23.6 months for HL, 29.0 months for ALCL, and 16.7 months for MF. *
Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.
Pathologie (Heidelb)
December 2023
Anatomic Pathology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain.
Article Synopsis
- Primary cutaneous CD30+ lymphoproliferative disorders (LPD) consist of various clonal T cell proliferations, including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (ALCL), which have different clinical features.
- A recent discovery has identified a specific DUSP22 translocation present in some cases of LyP and both cutaneous and systemic ALCL, leading to the classification of a new entity called "LyP with DUSP22t."
- Biopsies from cases with DUSP22 rearrangements display a unique biphasic pattern and a distinctive protein expression profile, characterized by retained T Cell Receptor (TCR) expression and positivity for
Primary cutaneous ALK-negative anaplastic large cell lymphoma: A case report.
Int J Surg Case Rep
December 2023
Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. Electronic address:
Article Synopsis
- Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (ALK-ALCL) is a rare and aggressive type of peripheral T-cell lymphoma, predominantly affecting lymph nodes and occasionally other tissues, with a higher prevalence in males.
- A case of primary cutaneous ALK-ALCL was presented, showing diverse cellular characteristics and confirmed through imaging techniques, with no recurrence observed over a six-month follow-up.
- The condition typically appears as red-brown skin lesions and requires differentiation from systemic ALCL, with prognosis influenced by the lesion's location and severity, emphasizing the importance of imaging for accurate diagnosis and treatment.
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
Clin Lymphoma Myeloma Leuk
February 2024
Seagen Inc., Bothell, WA.
Article Synopsis
- Primary cutaneous anaplastic large-cell lymphomas (pcALCLs) are a form of cutaneous T-cell lymphoma that consistently express CD30, unlike mycosis fungoides (MF), which shows varied expression.
- In a study called ALCANZA, patients with pcALCLs or CD30-positive MF treated with brentuximab vedotin (BV) had better outcomes in terms of response rates and longer survival compared to those receiving other standard therapies like methotrexate or bexarotene.
- The analysis found that in a real-world setting, patients treated with BV showed significantly improved treatment duration, response rates, progression-free survival, and healthcare resource use compared to those receiving other